Profile data is unavailable for this security.
About the company
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
- Revenue in USD (TTM)21.73m
- Net income in USD-91.17m
- Incorporated1992
- Employees323.00
- Locationbluebird bio Inc455 Grand Union BoulevardSOMERVILLE 02145United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.bluebirdbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 219.80m | 49.00 | -- | 4.95 | -- | 2,713.60 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Chromadex Corp | 83.17m | -3.53m | 219.82m | 106.00 | -- | 7.55 | -- | 2.64 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 222.02m | 84.00 | -- | -- | -- | 63.43 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 223.11m | 14.00 | -- | 2.50 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 224.14m | 233.00 | -- | -- | -- | 1.77 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 225.39m | 75.00 | -- | 1.75 | -- | 83.02 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 226.07m | 102.00 | -- | 2.69 | -- | 1,527.52 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| bluebird bio Inc | 21.73m | -91.17m | 232.23m | 323.00 | -- | 0.5867 | -- | 10.69 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 237.44m | 58.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 238.42m | 51.00 | -- | 2.63 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 238.44m | 158.00 | -- | 0.6946 | -- | 7.14 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 241.82m | 10.00 | -- | 2.13 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| Codexis Inc | 74.23m | -65.13m | 242.72m | 174.00 | -- | 3.06 | -- | 3.27 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 245.20m | 274.00 | -- | 1.18 | -- | 3.44 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Data as of Jul 22 2024. Currency figures normalised to bluebird bio Inc's reporting currency: US Dollar USD
33.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 14.09m | 7.31% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 10.36m | 5.37% |
| Granahan Investment Management, LLCas of 31 Mar 2024 | 7.71m | 4.00% |
| Columbia Wanger Asset Management LLCas of 31 Mar 2024 | 6.38m | 3.31% |
| Millennium Management LLCas of 31 Mar 2024 | 6.24m | 3.24% |
| Palo Alto Investors LPas of 31 Mar 2024 | 4.56m | 2.37% |
| Geode Capital Management LLCas of 31 Mar 2024 | 4.32m | 2.24% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 4.00m | 2.07% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.43m | 1.78% |
| Two Sigma Investments LPas of 31 Mar 2024 | 2.77m | 1.44% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
